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Abstract
Background: Rituximab (R) in combination with DHAP is a widely accepted salvage regimen for patients with
relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A common adverse effect of this protocol is renal
toxicity which may result in treatment discontinuation. Assuming that a lower single dose of cisplatin over several
days would reduce renal toxicity, our institution has chosen to administer cisplatin in a dosage of 25 mg/m2 per
day as a 3-h infusion over 4 consecutive days.
Methods: In this study, we analyzed the renal function of 122 patients with relapsed or refractory DLBCL treated
with R-DHAP at our institution. Overall, 256 R-DHAP cycles were administered. 31 (25 %), 61 (50 %), 14 (12 %) and
16 (13 %) patients received one, two, three or four R-DHAP courses, respectively.
Results: A glomerular filtration rate (GFR) decrease was observed after each R-DHAP cycle. However, in none of the
subgroups the median GFR was lower than 60 ml/min/1.73 m2. In most patients, only renal impairment stage I and
II was observed. Renal impairment stage III was seen in 10 % and stage IV only in 1 % of patients.
Conclusion: We conclude that a modified R-DHAP regimen with administration of cisplatin 25 mg/m2 over 4
consecutive cycles leads only to minimal renal toxicity.
Keywords: R-DHAP, DLBCL, Renal chemo toxicity
Background
The addition of the anti-CD20 monoclonal antibody ri-
tuximab (R) have significantly improved the outcome
and survival of patients with diffuse large B-cell lymph-
oma (DLBCL), and complete responses (CRs) after first
line therapy are observed in 75–80 % [1–3]. However,
approximately one-third of patients develop relapsed or
refractory disease [4]. For eligible patients, inductionche-
moimmunotherapy, and in case of chemosensitive dis-
ease, high-dose (HD) chemotherapy and autologous
stem cell transplantation (ASCT) are the current stand-
ard of care [5]. Such salvage therapies typically consist of
cytotoxic agents that have not been used in first line
therapy. One established regime in relapsed or refractory
DLBCL is R-DHAP. R-DHAP combines rituximab
(375 mg/m2), given intravenously (i.v.) one day before
chemotherapy, cisplatin (100 mg/m2), typically adminis-
tered i.v. by continuous infusion over 24 h, followed on
day 2 by cytarabine (2 g/m2) in a 3-h long infusion (re-
peated after 12 h), and oral dexamethasone (40 mg/d for
4 consecutive days) repeated after 21 days for 2–4 cycles.
However, this regimen is associated with severe adverse
effects that often require discontinuation of treatment,
such as myelosuppression, infections and renal toxicity.
For instance, in a phase II trial in relapsed non-Hodgkin
lymphoma evaluating the toxicity and efficacy of adding
4 doses of rituximab to a conventional DHAP regimen
grade III or IV nephrotoxicity was observed in 7 % of
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patients after two R-DHAP courses [6]. Moreover, in a
randomized phase III trial in relapsed or refractory
DLBCL comparing two salvage regimes, stage IV renal
toxicity occurred in 6 % of patients treated with three
cycles of conventional R-DHAP [7]. Because of the effi-
cacy of the R-DHAP regimen, attempt to reduce nephro-
toxicity e. g. by substitution of cisplatin with oxaliplatin
has been successfully made [8]. Another attractive ap-
proach to limit renal toxicity is to spread the cisplatin
application over several days. For example, cisplatin can
be administered for 4 consecutive days as a 3 h infusion,
consisting of 25 mg/m2 each. Moreover, the administra-
tion of cisplatin for several hours on four consecutive
days, instead of a 24 h infusion, allows treating patients
with this regimen on an outpatient basis. However, a
systematic evaluation of the toxicity and efficacy of this
modification is warranted. In the current study we there-
fore retrospectively analyzed 122 patients with relapsed
or refractory DLBCL treated with the modified R-DHAP
regimen at our institution. Our aims were to evaluate
the efficacy and renal toxicity of this salvage therapy
regimen.
Methods
Patient selection
All patients with relapsed or refractory DLBCL that were
treated with R-DHAP at our institution from July 2002
to July 2013 received the modified R-DHAP regimen,
under a hypothetical, but so far not verified, assumption
that a lower single dose of cisplatin over several days
would reduce renal toxicity. Overall, 122 patients were
included into this analysis. All patients had histologically
confirmed DLBCL. Clinical characteristics (age, gender,
stage at diagnosis), previous therapy, time to relapse and
serum creatinine before each individual and after the last
R-DHAP course were collected and retrospectively ana-
lyzed. This analysis was approved by the ethics commit-
tee University Hospital Heidelberg without an informed
consent of the patients with regard to its retrospectivity.
Research was carried out in compliance with the Helsinki
Declaration.
Modified R-DHAP regimen
Rituximab (375 mg/m2) was administered i.v. on day 1
using standard supportive therapy. Dexamethasone
(40 mg) was given orally for 4 consecutive days. Cytara-
bine (2 g/m2) was administered on day 2 as a 3-h infu-
sion and was repeated after 12 h. Cisplatin (25 mg/m2)
was applied on days 1 to 4 as a 3-h infusion. Dose modi-
fications were implemented according to renal function
as follows: At a glomerular filtration rate (GFR) below
60 ml/min/1.73 m2, cytarabine was reduced to 75 % of
the original dose, and to 50 % at a GFR below 50 ml/
min/1.73 m2. Cisplatin was reduced to 60 % and 50 %,
respectively. A GFR below 30 ml/min/1.73 m2 was con-
sidered a contraindication for cytarabine und cisplatin.
Cycles were repeated every three weeks. For prevention
of chemotherapy-induced nausea and vomiting, intensi-
fied oral supportive medication (dexamethasone 8 mg
and granisetron hydrochloride 2 mg days 1 to 4, aprepi-
tant 125 mg day 1, aprepitant 80 mg day 1 to 6) was
used [9].
Assessment of clinical responses
Response to R-DHAP was evaluated by clinical examin-
ation and computed tomography scan of the involved
lymph node regions according to standardized response
criteria for non-Hodgkin lymphomas [10].
Assessment of renal toxicity
Renal toxicity was assessed by measuring serum creatin-
ine levels up to three days before each R-DHAP cycle
and two to three weeks after termination of each R-
DHAP cycle. GFR was calculated according to the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation [11]. GFR above 90 ml/min/1.73 m2
was considered normal renal function. GFRs of 89-60,
59-30, 29-15 and <15 ml/min/1.73m2were graded as
stage II, III, IV or V renal function impairment.
Statistical analysis
Patients were grouped according to the overall number
of received R-DHAP courses (minimum one, maximum
four). Descriptive statistics and comparison between the
groups was performed by Prism 5.03. Data are given as
absolute numbers and percentage, and if not otherwise
stated as mean and standard deviation (SD). To increase
visual evidence and to allow better comparison, GFR
levels are described as mean and SD in the text and il-
lustrated as box plots (minimum, first quartile, median,
third quartile and maximum, Fig. 1 and 3). For compari-
son of categorical variables (gender, stage at first diagno-
sis, previous therapy, time to relapse after last treatment
and response to R-DHAP) Freeman-Halton extension of
Fisher's Exact test was used. To identify differences
among groups’ means (age at first diagnosis, age at first
R-DHAP and duration between last treatment and first
R-DHAP) an analysis of variance was performed. Mean
differences in individual pairwise comparisons of pre-
and post-treatment GFR values were made using paired
two tailed student's t test. A P < 0.05 was considered sta-
tistically significant.
Results
Patient characteristics
A total of 122 patients with relapsed or refractory
DLBCL were treated with R-DHAP as second-line ther-
apy at our institution. The mean age at first R-DHAP
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was 57 (SD 12) years, and the male:female ratio was 2:1.
113 (93 %) patients had previously received CHOP-like
treatment. In 96 (79 %) patients, first line therapy in-
cluded rituximab. Most patients had progressive disease
or relapsed within 12 months after first treatment. De-
tailed patient characteristics and treatment details are
summarized in Table 1.
Exposure and response to R-DHAP treatment
Overall, 256 R-DHAP cycles were administered. 31
(25 %), 61 (50 %), 14 (12 %) and 16 (13 %) patients re-
ceived one, two, three or four R-DHAP courses, respect-
ively. Dose adjustments were applied in only 5 (4 %)
patients who in total received 11 R-DHAP courses. In
one patient cytarabine was reduced to 50 % due to ad-
vanced age (>70 years) and poor general condition. One
patient received carboplatin instead of cisplatin due to
stage III renal impairment. In two patients, both cytara-
bine and cisplatin dose adjustments were necessary due
to a GFR <50 ml/min/1.73 m2. In one patient, reasons
for and extent of R-DHAP dose adjustments were not
documented. In 5 patients the response to R-DHAP
treatment was not available. 19 (16 %), 6 (5 %), 39
(32 %) and 18 (15 %) patients achieved CR, CRu
(complete response unconfirmed), partial remission (PR)
and stable disease (StD), respectively. 35 (29 %) patients
had progressive disease (PD), which predominantly oc-
curred after the first two cycles of R-DHAP (Table 1).
Renal toxicity
In patients who received one cycle of R-DHAP the initial
mean GFR was 91 (SD 25) ml/min/1.73 m2. 17 (55 %)
patients had normal renal function. Ten (32 %) and four
(13 %) patients showed an initial stage II and III renal
impairment. After one course of R-DHAP, the GFR
remained stable (mean 84, SD 34 ml/min/1.73 m2, P =
0.06, Fig. 1a). We detected individual deterioration in
renal function by one toxicity stage in nine patients and
by two toxicity stages in two patients (Fig. 2a).
Fig. 1 GFR in dependency of the number of R-DHAP courses. The diagrams show the GFR separately for patients who underwent one (a, n = 31),
two (b, n = 61), three (c, n = 14) or four (d, n = 16) courses of R-DHAP, respectively. The data are presented as minimum, first quartile, median, third
quartile and maximum
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In patients who received two courses of R-DHAP, the
initial mean GFR significantly decreased from 97 (SD
20) ml/min/1.73 m2 to 92 (SD 22) ml/min/1.73 m2
after the first chemotherapy cycle (P < 0.01) and to 88
(SD 20) ml/min/1.73 m2 after the second course of R-
DHAP (P < 0.001, Fig. 1b). Before treatment, 42 (69 %)
patients had normal renal function. Eight of these pa-
tients had worsening kidney function by one stage and
one by two stages. In all but one of 15 (25 %) patients
who showed stage II renal impairment before R-DHAP
kidney function remained stable or even improved
after two courses of therapy. In three (5 %) patients
who had stage III renal function impairment before
therapy, no decrease in renal function was observed
(Fig. 2b). In one patient initial renal function was not
available.
A significant GFR decrease in patients who have been
treated with three R-DHAP courses from initially 94 (SD
21) to 84 (SD 27) ml/min/1.73 m2 after the third course
of therapy (P = 0.04) was observed. While the GFR was
almost stable over the first two cycles of chemotherapy
the main decline occurred after the third R-DHAP cycle,
where the mean GFR fell by 7 ml/min/1.73 m2 (Fig. 1c).
We noticed a worsening in renal function from stage I
to stage II in three patients and from stage II to stage III
in two patient of this subgroup (Fig. 2c).
Table 1 Patient characteristics and response to R-DHAP
Overall
cohort
1 cycle 2 cycles 3 cycles 4 cycles P-values
R-DHAP R-DHAP R-DHAP R-DHAP
Patients, n (%) 122 (100) 31 (25) 61 (50) 14 (12) 16 (13) /
Gender, n (%) 0.17
Male 82 (67) 20 (65) 37 (61) 11 (79) 14 (88)
Female 40 (33) 11 (35) 24 (39) 3 (21) 2 (12)
First diagnosis and previous Tx
Mean age at first diagnosis (SD) 53 (12) 53 (13) 54 (11) 51 (13) 54 (12) 0.73
Stage at first diagnosis, n (%) 0.01
I 7 (6) 1 (3) 2 (3) 4 (29) 0 (0)
II 26 (21) 4 (13) 14 (23) 3 (21) 5 (31)
III 39 (32) 12 (39) 19 (31) 3 (21) 5 (31)
IV 48 (39) 13 (42) 26 (43) 3 (21) 6 (38)
Not known 2 (2) 1 (3) 0 (0) 1 (7) 0 (0)
CHOP-like therapy, n (%) 113 (93) 29 (94) 58 (95) 12 (86) 14 (88) 0.35
Other, n (%) 8 (6) 2 (6) 2 (3) 2 (14) 2 (12)
Not known, n (%) 1 (1) 0 (0) 1 (2) 0 (0) 0 (0)
Rituximab-containing, n (%) 96 (79) 30 (97) 47 (77) 10 (71) 9 (56) 0.01
Relapse
TTR after last treatment, n (%) 0.01
Refractory or <12 months 79 (65) 26 (84) 40 (66) 6 (43) 7 (44)
≥12 months 43 (35) 5 (16) 21 (34) 8 (57) 9 (56)
Mean age at 1. R-DHAP (SD) 57 (12) 56 (15) 57 (11) 56 (13) 57 (13) 0.98
Months between last treatment and 1. R-DHAP, mean (SD) 19 (29) 8 (15) 17 (28) 43 (47) 27 (23) <0.01
Response to R-DHAP, n (%) <0.01
CR 19 (16) 0 (0) 11 (18) 5 (36) 3 (19)
CRu 6 (5) 0 (0) 5 (8) 0 (0) 1 (6)
PR 39 (32) 3 (10) 18 (30) 6 (43) 12 (75)
StD 18 (15) 5 (16) 11 (18) 2 (14) 0 (0)
PD 35 (29) 18 (58) 16 (26) 1 (7) 0 (0)
Not known 5 (4) 5 (16) 0 (0) 0 (0) 0 (0)
CHOP cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone, CR(u) complete response (unconfirmed), PBSC peripheral blood stem cell collection, PD
progressive disease, PR partial remission, R-DHAP rituximab, dexamethasone, cytarabine, cisplatin, StD stable disease, SD standard deviation, TTR time to relapse.
Statistically significant P-values are indicated in bold.
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Similarly, in patients who received four R-DHAP cy-
cles, the initial mean GFR of 96 (SD 14) ml/min/1.73 m2
remained stable over the first two cycles. After the third
and fourth course of R-DHAP, the mean GFR signifi-
cantly fell to 87 (SD 20, P = 0.01) and 83 (SD 22, P <
0.01) ml/min/1.73 m2 (Fig. 1d). In this subgroup we
found a decrease in renal function from stage I to stage
II in six patients and from stage II to stage III in two pa-
tients (Fig. 2d).
Figure 3 summarizes the GFR separated by subgroup
in dependency of the course of R-DHAP therapy.
Discussion
We here performed an analysis of 122 patients with re-
lapsed or refractory DLBCL treated with a modified R-
DHAP regimen. Contrasting the practice of other cen-
ters, the total dose of cisplatin was maintained but
spread over 4 consecutive days to minimize renal tox-
icity. Our aim was to assess renal toxicity associated
with this regimen using a “real-life” population not
selected for clinical trials. This series was homogeneous
according to the diagnosis relapsed or refractory
DLBCL, gender distribution, previous CHOP-like ther-
apy and age at first R-DHAP but heterogeneous accord-
ing to stage at first diagnosis, time to elapse after last
treatment and duration between last treatment and first
R-DHAP among the four R-DHAP groups.
We show that the modified R-DHAP regimen as ad-
ministered in our institution is efficient and safe in this
patient group. We observed chemosensitivity in 68 % of
patients, and PD occurred in only one third of the pa-
tients. This is in accordance with response rates reported
for conventional R-DHAP regimens applied in prospect-
ive trials, where response to therapy was observed in
76 % of the patients (7).
Importantly, modified R-DHAP did not lead to severe
renal impairment in our cohort. When analyzing GFR
according to the number of cycles received, renal im-
pairment stage III was observed in less than 10 % and
stage IV only in less than 1 % of patients, and none of
Fig. 2 Renal function during R-DHAP treatment by stage. GFR and corresponding renal function by stage during the course of therapy is shown
separately for every single patient who underwent one (a, n = 31), two (b, n = 61), three (c, n = 14) or four (d, n = 16) cycles of R-DHAP
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the subgroups had an initial average GFR of less than
60 ml/min/1.73 m2. Within subgroups we found an
additive renal toxicity over the course of R-DHAP treat-
ment, but a statistically significant GFR decrease was ob-
served only after the third and fourth R-DHAP course.
A direct prospective comparison between modified and
conventional R-DHAP regimens has not been conducted
yet and unfortunately, comparisons of retrospective
results published by different centers on non-modified
R-DHAP are hampered by the heterogeneity of patient
cohorts and treatment approaches [7, 8, 12, 13].
In particular, renal toxicity was not assessed in detail
and in relation to the number of treatment cycles re-
ceived the majority of published studies using conven-
tional R-DHAP. In a randomized phase III trial in
relapsed or refractory DLBCL comparing the salvage re-
gimes R-DHAP versus R-ICE (ifosfamide, carboplatin,
etoposide), stage IV renal toxicity was observed in 11 of
194 patients (6 %) treated with conventional R-DHAP
over the course of three cycles (7). In contrast, we ob-
served no stage IV renal toxicity in patients who re-
ceived three or even four courses of modified R-DHAP.
To the best of our knowledge this is the first de-
tailed evaluation of renal function during R-DHAP
treatment in a large series of relapsed or refractory
DLBLC patients. Our data show that the administra-
tion of 25 mg/m2 cisplatin for 4 consecutive days in a
3 h infusion as a component of the R-DHAP regimen
is efficient in relapsed or refractory DLBCL and leads to a
tolerable additive renal toxicity over up to four R-DHAP
courses. Furthermore, this study demonstrates that a
detailed analysis of renal function impairment after each
chemotherapy cycle is required to assure comparability
between different chemotherapy protocols.
Conclusion
R-DHAP (rituximab, cisplatin, cytarabine, dexametha-
sone) is an accepted salvage regimen for relapsed or re-
fractory diffuse large B-cell lymphoma patients. Assuming
that a lower single dose of cisplatin over several days
would reduce renal toxicity, the total dose of cisplatin
(100 mg/m2) was spread over 4 consecutive days. Renal
impairment stage III was seen in 10 % and stage IV only
in 1 % of patients indicating minimal renal toxicity of the
modified R-DHAP regimen.
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